Amyloid deposit corresponds to technetium-99m-pyrophosphate accumulation in abdominal fat of patients with transthyretin cardiac amyloidosis.
Abdominal fat
Amyloidosis
Bone-avid tracer
Heart failure
Transthyretin
Journal
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
ISSN: 1532-6551
Titre abrégé: J Nucl Cardiol
Pays: United States
ID NLM: 9423534
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
03
09
2021
accepted:
19
11
2021
pubmed:
30
12
2021
medline:
14
1
2023
entrez:
29
12
2021
Statut:
ppublish
Résumé
Radionuclide imaging using bone-avid tracers plays a critical role in diagnosing transthyretin cardiac amyloidosis (ATTR-CA), but technetium-99m-pyrophosphate (PYP) rarely allows the detection of extracardiac amyloid infiltration. We retrospectively investigated the frequency of PYP uptake in the subcutaneous abdominal fat of patients with ATTR-CA and its relevance to the results of fine-needle aspiration biopsy (FNAB) of this tissue. Chest-centered images of PYP scintigraphy were obtained 2 h after the intravenous injection of the tracer (20 mCi), and the frequency of PYP uptake in the subcutaneous abdominal fat was evaluated. Amyloid deposits of fat smears taken by subcutaneous abdominal fat FNAB were assessed by Congo red staining. Twenty-four patients with ATTR-CA were included. Ten (41.7%) patients showed some PYP uptake in the subcutaneous abdominal fat (positive PYP group), and 14 patients did not (negative PYP group). Amyloid deposits were detected by subcutaneous abdominal fat FNAB in 7/10 patients (70.0%) of the positive PYP group versus 0/14 patients (0%) of the negative PYP group, and the difference was significant. In patients with ATTR-CA, abnormal PYP uptake in the subcutaneous abdominal fat could reflect the regional amyloid deposition confirmed by FNAB of this tissue.
Sections du résumé
BACKGROUND
Radionuclide imaging using bone-avid tracers plays a critical role in diagnosing transthyretin cardiac amyloidosis (ATTR-CA), but technetium-99m-pyrophosphate (PYP) rarely allows the detection of extracardiac amyloid infiltration. We retrospectively investigated the frequency of PYP uptake in the subcutaneous abdominal fat of patients with ATTR-CA and its relevance to the results of fine-needle aspiration biopsy (FNAB) of this tissue.
METHODS
Chest-centered images of PYP scintigraphy were obtained 2 h after the intravenous injection of the tracer (20 mCi), and the frequency of PYP uptake in the subcutaneous abdominal fat was evaluated. Amyloid deposits of fat smears taken by subcutaneous abdominal fat FNAB were assessed by Congo red staining.
RESULTS
Twenty-four patients with ATTR-CA were included. Ten (41.7%) patients showed some PYP uptake in the subcutaneous abdominal fat (positive PYP group), and 14 patients did not (negative PYP group). Amyloid deposits were detected by subcutaneous abdominal fat FNAB in 7/10 patients (70.0%) of the positive PYP group versus 0/14 patients (0%) of the negative PYP group, and the difference was significant.
CONCLUSIONS
In patients with ATTR-CA, abnormal PYP uptake in the subcutaneous abdominal fat could reflect the regional amyloid deposition confirmed by FNAB of this tissue.
Identifiants
pubmed: 34964085
doi: 10.1007/s12350-021-02890-6
pii: 10.1007/s12350-021-02890-6
doi:
Substances chimiques
Diphosphates
0
Technetium
7440-26-8
Prealbumin
0
Radiopharmaceuticals
0
Technetium Tc 99m Pyrophosphate
5L76I61H2B
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3126-3136Informations de copyright
© 2021. The Author(s) under exclusive licence to American Society of Nuclear Cardiology.
Références
Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol 2019;26:2065-123.
doi: 10.1007/s12350-019-01760-6
Singh V, Falk R, Di Carli MF, Kijewski M, Rapezzi C, Dorbala S. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol 2019;26:158‐73.
doi: 10.1007/s12350-018-01552-4
Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404‐12.
doi: 10.1161/CIRCULATIONAHA.116.021612
Sperry BW, Gonzalez MH, Brunken R, Cerqueira MD, Hanna M, Jaber WA. Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis. J Nucl Cardiol 2019;26:1630‐7.
doi: 10.1007/s12350-017-1166-7
Quarta CC, Gonzalez-Lopez E, Gilbertson JA, Botcher N, Rowczenio D, Petrie A, et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 2017;38:1905‐8.
doi: 10.1093/eurheartj/ehx047
Takahashi K, Sasaki D, Sakaue T, Enomoto D, Uemura S, Okura T, et al. Extracardiac accumulation of technetium-99m-pyrophosphate in transthyretin cardiac amyloidosis. JACC Case Rep 2021;3:1069‐74.
doi: 10.1016/j.jaccas.2021.02.015
Surawicz B, Childers R, Deal BJ, Gettes LS, Bailey JJ, Gorgels A, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part III: Intraventricular conduction disturbances: A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: Endorsed by the International Society for Computerized Electrocardiology. J Am Coll Cardiol 2009;53:976‐81.
doi: 10.1016/j.jacc.2008.12.013
Kim D, Lee GY, Choi JO, Kim K, Kim SJ, Jeon ES. Associations of electrocardiographic parameters with left ventricular longitudinal strain and prognosis in cardiac light chain amyloidosis. Sci Rep 2019;9:7746.
doi: 10.1038/s41598-019-44245-9
Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: Characterization by a distinctive voltage/mass relation. Am J Cardiol 1982;49:9‐13.
doi: 10.1016/0002-9149(82)90270-3
Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015;28:1-39.e14.
doi: 10.1016/j.echo.2014.10.003
Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2016;29:277‐314.
doi: 10.1016/j.echo.2016.01.011
Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a common standard for 2D speckle tracking echocardiography: Consensus document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr 2015;28:183‐93.
doi: 10.1016/j.echo.2014.11.003
Bokhari S, Cerqueira MD. Tc-99m-PYP imaging for cardiac amyloidosis: Defining the best protocol before the flood gates burst. J Nucl Cardiol 2020;27:1816‐9.
doi: 10.1007/s12350-020-02273-3
Misumi Y, Ueda M, Yamashita T, Masuda T, Kinoshita Y, Tasaki M, et al. Novel screening for transthyretin amyloidosis by using fat ultrasonography. Ann Neurol 2017;81:604‐8.
doi: 10.1002/ana.24914
Shidham VB, Hunt B, Jardeh SS, Barboi AC, Devata S, Hari P. Performing and processing FNA of anterior fat pad for amyloid. J Vis Exp 2010;44:1747.
Naiki H, Sekijima Y, Ueda M, Ohashi K, Hoshii Y, Shimoda M, et al. Human amyloidosis, still intractable but becoming curable: Τhe essential role of pathological diagnosis in the selection of type-specific therapeutics. Pathol Int 2020;70:191‐8.
doi: 10.1111/pin.12902
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 2013;48:452‐8.
doi: 10.1038/bmt.2012.244
Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation 2017;135:1357‐77.
doi: 10.1161/CIRCULATIONAHA.116.024438
Suhr OB, Lundgren E, Westermark P. One mutation, two distinct disease variants: Unravelling the impact of transthyretin amyloid fibril composition. J Intern Med 2017;281:337‐47.
doi: 10.1111/joim.12585
Ikeda S, Sekijima Y, Tojo K, Koyama J. Diagnostic value of abdominal wall fat pad biopsy in senile systemic amyloidosis. Amyloid 2011;18:211‐5.
doi: 10.3109/13506129.2011.623199
Harb SC, Haq M, Flood K, Guerrieri A, Passerell W, Jaber WA, et al. National patterns in imaging utilization for diagnosis of cardiac amyloidosis: A focus on Tc99m-pyrophosphate scintigraphy. J Nucl Cardiol 2017;24:1094‐7.
doi: 10.1007/s12350-016-0478-3
Hutt DF, Quigley AM, Page J, Hall ML, Burniston M, Gopaul D, et al. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging 2014;15:1289‐98.
doi: 10.1093/ehjci/jeu107